Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Zhejiang Teruisi Pharmaceutical
Huzhou, Zhejiang, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Teruisi develops oncology-focused antibody therapeutics and biosimilars. Its bevacizumab biosimilar (recombinant humanized anti-VEGF monoclonal antibody, TRS003) is in a Phase 3 interchangeability study in metastatic colorectal cancer, while its proprietary CD20-targeting ADC TRS005 for relapsed/refractory CD20 positive diffuse large B-cell lymphoma has reached pivotal Phase 2 in China and received NMPA CDE breakthrough therapy designation. Multiple additional antibody and ADC programs, including trastuzumab and rituximab biosimilars and novel candidates such as TRS013 and FIT012/TRS008, are in preclinical to early clinical development.[3][8][12]
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodyAntibodyAntibody-drug conjugateBiological products
- Industry
- Biotech
02
Partnerships
EpimAb Biotherapeutics (development collaboration for bispecific antibody FIT012/TRS008 for China)[4]MabPlex International (CDMO partnership for late-stage development, PPQ, and commercialization support for ADC TRS005)[12]
Beyond the preview
Go deeper on Zhejiang Teruisi Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zhejiang Teruisi Pharmaceutical.